Work

Nerandomilast and the Evolving Therapeutic Paradigm in Pulmonary Fibrosis: From Mechanism to Clinical Efficacy

Year: 2026

Type: article

Abstract: ABSTRACT The recent Phase III FIBRONEER trials establish nerandomilast, a novel oral phosphodiesterase 4B (PDE4B) inhibitor, as an effective therapy for idiopathic and progressive pulmonary fibrosis. By elevating cyclic adenosine monophosphate (cAMP), it uniquely dual‐targets the NLRP3 inflammasome and TGF‐β pathway, addressing both inflammation and fibrosis. The trials demonstrated significant slowing of lung function decline, with a manageable safety profile. Critically, its efficacy on background antifibrotic therapy provides robust evidence for viable combination regimens, thereby ushering in a new era of combination therapy for this refractory disease. This marks a paradigm shift, offering renewed hope and paving the way for multi‐targeted treatment strategies, although longer‐term outcomes warrant further study.

Source: iNew Medicine

DOI: 10.1002/inm3.70052

Authors: Qianwen Bai, Jia Deng, Hongquan Wang, Yao Yao, Tao Wang

Institutions: First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease

Language: English

Topic: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funder: National Natural Science Foundation of China